J&J’s first-quarter profit beats estimates even as Stelara sales disappoint
Drug and device maker raised its full-year revenue and adjusted earnings forecast
- J&J’s first-quarter profit beats estimates even as Stelara sales disappoint CTV News —
- J&J’s First-Quarter Sales Grow on Cancer-Drug Strength Wall Street Journal —
- Johnson & Johnson Non-GAAP EPS of $2.70 beats by $0.02, revenue of $24.06B beats by $450M Seeking Alpha —
- Earnings Snapshot: Johnson & Johnson tops Q1 expectations; boosts full-year outlook and increases quarterly dividend Seeking Alpha —
- Johnson & Johnson in charts: Q1 Innovative Medicine rises 11.2% as DARZALEX leads growth Seeking Alpha —